Dear Medical Provider:

We are writing to explain the participation of your patient in the Center for Prevention of Progression of Blood Cancers (CPOP), a research project organized by the Dana-Farber Cancer Institute/Brigham and Women's Cancer Center (DF/BWCC).

The clinic was created in order to study and understand why some patients with these precursor conditions go on to develop progressive disease, while others do not show progression — and to develop better targeted therapeutic agents to prevent progression, or even eliminate the disease before it leads to symptoms.

We are specifically focusing our attention on the following precursor conditions: early cases of chronic lymphocytic leukemia called monoclonal B cell lymphocytosis (MBL); early cases of multiple myeloma or Waldenström’s Macroglobulinemia called monoclonal gammopathy of undetermined significance (MGUS) and Smoldering multiple myeloma or Waldenström’s Macroglobulinemia; and early cases of myelodysplastic syndrome (MDS) and myeloproliferative disorders.

Your patient qualifies for this study because of his/her diagnosis with one of these disorders. Participation in this study will help us understand the causes and help us move toward prevention and improved treatment.

As part of the study, participants complete a medical questionnaire and allow us to review their medical records for research purposes. The participants also agree to donate a blood sample, a bone marrow, if applicable, and a buccal sample for research. It is important to note that participants will not undergo tests or procedures that are not required as part of their routine clinical care. They will only be asked to provide an additional sample from tissue that is obtained for clinical indications. Your patient has agreed to these arrangements and will need the following to be drawn during their next scheduled visit: 30-60 cc of peripheral blood and/or 5-20 cc of bone marrow. During this appointment, they will bring all required materials, along with further instructions.

All information that contains personal identifiers will be held in strict confidence and will not be released without the patient’s signed consent.

You can find additional information about this important study at: www.danafarber.org/cpop and http://pcrowd.dana-farber.org/.

If you have any questions, please e-mail us at precursor@partners.org or call 617.582.8664.

Sincerely yours,

Robert Soiffer, MD
Professor of Medicine
Dana-Farber Cancer Institute

Irene M. Ghobrial, MD
Associate Professor of Medicine
Dana-Farber Cancer Institute

Protocol # 14-174